Delving into the Latest Updates on Shanghai Pailong Biotechnology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Respiratory Diseases

Small molecule drug

Chemical drugs

ASO

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	7
Endocrinology and Metabolic Disease	2

Top 5 Drug Type	Count

Small molecule drug	4
Chemical drugs	2
ASO	1

Top 5 Target	Count

KIF18A(kinesin family member 18A)	2
MTA-PRMT5(MTA-Cooperative PRMT5)	1
PPI(Cyclophilin peptidylprolyl isomerases)	1
CDK7(Cyclin-dependent kinase 7)	1
PARP7(TCDD-inducible poly [ADP-ribose] polymerase)	1

一项在MTAP纯合型缺失的局部晚期或转移性胰腺导管腺癌（PDAC）受试者中评价GTA182联合紫杉醇（白蛋白结合型）+吉西他滨（AG治疗方案）或联合伊立替康脂质体、氟尿嘧啶、亚叶酸钙（nal-IRI+5-FU/LV治疗方案）治疗的安全性、耐受性、药代动力学和有效性的I期研究

[Translation] A phase I study evaluating the safety, tolerability, pharmacokinetics, and efficacy of GTA182 in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) homozygous loss of MTAP in combination with paclitaxel (albumin-bound) + gemcitabine (AG regimen) or in combination with irinotecan liposomes, fluorouracil, and leucovorin (nal-IRI + 5-FU/LV regimen).

Ia期主要目的：确定GTA182联合AG治疗方案或联合nal-IRI+5-FU/LV治疗方案的Ⅱ期推荐剂量（RP2D）。评估GTA182联合AG治疗方案或联合nal-IRI+5-FU/LV治疗方案在MTAP纯合型缺失局部晚期或转移性PDAC受试者中的安全性和耐受性。Ib期主要目的：评估在Ia期推荐的联合剂量下GTA182联合AG治疗方案或联合nal-IRI+5-FU/LV治疗方案在MTAP纯合型缺失局部晚期或转移性PDAC受试者中的安全性和耐受性；评估在Ia期推荐的联合剂量下GTA182联合AG治疗方案或联合nal-IRI+5-FU/LV治疗方案在MTAP纯合型缺失局部晚期或转移性PDAC受试者中的初步有效性。

[Translation]

The primary objective of Phase Ia was to determine the Phase II recommended dose (RP2D) of GTA182 in combination with AG or in combination with nal-IRI + 5-FU/LV. The safety and tolerability of GTA182 in combination with AG or in combination with nal-IRI + 5-FU/LV in patients with homozygous deletion of MTAP-positive locally advanced or metastatic PDAC were also assessed. The primary objective of Phase Ib was to assess the safety and tolerability of GTA182 in combination with AG or in combination with nal-IRI + 5-FU/LV at the Phase Ia recommended dose in patients with homozygous deletion of MTAP-positive locally advanced or metastatic PDAC; and to assess the preliminary efficacy of GTA182 in combination with AG or in combination with nal-IRI + 5-FU/LV at the Phase Ia recommended dose in patients with homozygous deletion of MTAP-positive locally advanced or metastatic PDAC.

Start Date18 Mar 2026

Sponsor / Collaborator

Shanghai Pailong Biotechnology Co., Ltd.

CTR20254181

/ RecruitingPhase 1

评价GTA182联合伏美替尼在MTAP纯合型缺失的局部晚期或转移性非小细胞肺癌（NSCLC）受试者中的安全性、耐受性、药代动力学以及初步有效性的剂量递增和剂量扩展的I期临床研究

[Translation] A phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and initial efficacy of GTA182 in combination with vortexinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) homozygous absence of MTAP.

Ia期（剂量递增阶段）主要目的：评估GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的安全性和耐受性，以确定扩展期推荐的联合剂量。次要目的：描述GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的药代动力学特征；评估GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的初步有效性。探索性目的：探索与GTA182疗效相关的生物标志物。 Ib期（剂量扩展阶段）主要目的：评估在Ia期推荐的联合剂量下GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的安全性和耐受性，以确认联合用药RP2D。次要目的：评估在Ia期推荐的联合剂量下GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的药代动力学特征；评估在Ia期推荐的联合剂量下GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的初步有效性，为后续临床试验推荐剂量选择提供依据。探索性目的：探索与GTA182疗效相关的生物标志物。

[Translation]

Phase Ia (Dose Escalation Phase) Primary Objective: To evaluate the safety and tolerability of GTA182 in combination with voreminib in patients with MTAP homozygous deletion locally advanced or metastatic NSCLC to determine the recommended combination dose for the extension phase. Secondary Objectives: To describe the pharmacokinetic characteristics of GTA182 in combination with voreminib in patients with MTAP homozygous deletion locally advanced or metastatic NSCLC; to assess the preliminary efficacy of GTA182 in combination with voreminib in patients with MTAP homozygous deletion locally advanced or metastatic NSCLC. Exploratory Objectives: To explore biomarkers related to the efficacy of GTA182. Phase Ib (Dose Extension Phase) Primary Objective: To evaluate the safety and tolerability of GTA182 in combination with voreminib at the Phase Ia recommended combination dose in patients with MTAP homozygous deletion locally advanced or metastatic NSCLC to confirm the RP2D of the combination therapy. Secondary objectives: To evaluate the pharmacokinetic characteristics of GTA182 in combination with vortexinib at the recommended combination dose in Phase Ia patients with MTAP homozygous deletion locally advanced or metastatic NSCLC; to assess the preliminary efficacy of GTA182 in combination with vortexinib at the recommended combination dose in Phase Ia patients with MTAP homozygous deletion locally advanced or metastatic NSCLC, providing a basis for dose selection in subsequent clinical trials. Exploratory objectives: To explore biomarkers associated with the efficacy of GTA182.

Start Date03 Nov 2025

Sponsor / Collaborator

Shanghai Pailong Biotechnology Co., Ltd.

CTR20243795

/ RecruitingPhase 1

评价GTA182在MTAPnull/lost的晚期实体瘤受试者中的安全性、耐受性的剂量递增和剂量扩展的I期临床研究

[Translation] A Phase I clinical study evaluating the safety, tolerability, and dose escalation and dose expansion of GTA182 in patients with MTAPnull/lost advanced solid tumors.

Ia期（剂量递增阶段）（1）主要目的：评估GTA182在MTAPnull/lost晚期实体瘤受试者中的安全性和耐受性，以确定扩展期推荐剂量（RDEs）或最大耐受剂量（MTD）（如存在）。（2）次要目的：评估GTA182在MTAPnull/lost晚期实体瘤受试者中的药代动力学特征；评估GTA182在MTAPnull/lost晚期实体瘤受试者中的初步有效性。（3）探索性目的：探索与GTA182疗效相关的生物标志物。Ib期（剂量扩展阶段）（1）主要目的：评估在RDEs剂量下GTA182在MTAPnull/lost晚期实体瘤受试者中的安全性和耐受性，以确认II期推荐剂量（RP2D）。（2）次要目的：评估在RDEs剂量下GTA182在MTAPnull/lost晚期实体瘤受试者中的药代动力学特征；评估在RDEs剂量下GTA182在MTAPnull/lost晚期实体瘤受试者中的初步有效性，为后续临床试验推荐剂量和适应症选择提供依据。（3）探索性目的：探索与GTA182疗效相关的生物标志物。

[Translation]

Phase Ia (Dose Escalation Phase) (1) Primary Objective: To assess the safety and tolerability of GTA182 in patients with MTAPnull/lost advanced solid tumors to determine the recommended dose (RDEs) or maximum tolerated dose (MTD) for the extended phase (if applicable). (2) Secondary Objective: To assess the pharmacokinetic characteristics of GTA182 in patients with MTAPnull/lost advanced solid tumors; to assess the preliminary efficacy of GTA182 in patients with MTAPnull/lost advanced solid tumors. (3) Exploratory Objective: To explore biomarkers related to the efficacy of GTA182. Phase Ib (Dose Expansion Phase) (1) Primary Objective: To assess the safety and tolerability of GTA182 at RDEs in patients with MTAPnull/lost advanced solid tumors to confirm the recommended dose (RP2D) for the phase II phase. (2) Secondary objectives: To evaluate the pharmacokinetic characteristics of GTA182 at RDE doses in MTAPnull/lost advanced solid tumor subjects; to evaluate the preliminary efficacy of GTA182 at RDE doses in MTAPnull/lost advanced solid tumor subjects, providing a basis for recommended doses and indications selection in subsequent clinical trials. (3) Exploratory objectives: To explore biomarkers related to the efficacy of GTA182.

Start Date30 Oct 2024

Sponsor / Collaborator

Shanghai Pailong Biotechnology Co., Ltd.

100 Clinical Results associated with Shanghai Pailong Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Pailong Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Pailong Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Pailong Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

4

1

Preclinical

Phase 1

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

GTAEXS-617 ( CDK7 )	Advanced Malignant Solid Neoplasm More	Phase 1/2
GTA-182 ( MTA-PRMT5 )	Advanced Malignant Solid Neoplasm More	Phase 1
PPI modulator (Gt Apeiron) ( PPI )	Solid tumor More	Preclinical
WO2025201413 ( POLQ )Patent Mining	Neoplasms More	Discovery
KIF18A inhibitors(Apeiron Therapeutics) ( KIF18A )	Uterine Cervical Dysplasia More	Discovery